Obesity News

Individuals with type 2 diabetes who received semaglutide had lower probability for medical care related to tobacco dependence compared with other antidiabetes medications, the results of a study in the Annals of Internal Medicine showed.

The FDA is warning providers and patients that dosing errors with compounded injectable semaglutide may be leading to adverse events, according to a press release.

There are many important factors primary care providers must consider when prescribing popular anti-obesity medications, according to experts.

New prescriptions of GLP-1 receptor agonists for the treatment of obesity have increased significantly among individuals without type 2 diabetes in the last decade, according to a study in Annals of Internal Medicine.

In a single-center cohort of patients with heart failure and obesity, weight-loss surgery led to improved clinical outcomes including reduced BMI and HbA1c and less reliance on diuretics, researchers reported.

Researchers found that adults with overweight or obesity lost more weight with tirzepatide than semaglutide in a head-to-head comparison of the medications using electronic medical records data.

People with excess adiposity in young adulthood were more likely to have adverse cardiac structure and function later in life compared with people without it, researchers reported in the European Heart Journal.

About 40% of cancer cases and nearly half of cancer deaths among U.S. adults aged 30 years or older can be attributable to modifiable risk factors, according to a study led by American Cancer Society researchers.

Semaglutide was associated with an increased risk for nonarteritic anterior ischemic optic neuropathy — a form of optic neuropathy that can cause blindness — in adults with type 2 diabetes or obesity, recent data show.

In a Healio exclusive, Andres J. Acosta, MD, PhD, highlights data demonstrating that the MyPhenome test may serve as a biomarker to determine whether a patient with obesity will be a “good responder” to semaglutide.